MP32-14 ASSOCIATION OF BASELINE PLASMA CAFFEINE LEVELS AND RELATED METABOLITES WITH TIME TO GRADE GROUP PROGRESSION IN MEN WITH PROSTATE CANCER ON ACTIVE SURVEILLANCE

Abstract

You have accessJournal of UrologyProstate Cancer: Epidemiology & Natural History II (MP32)1 Sep 2021MP32-14 ASSOCIATION OF BASELINE PLASMA CAFFEINE LEVELS AND RELATED METABOLITES WITH TIME TO GRADE GROUP PROGRESSION IN MEN WITH PROSTATE CANCER ON ACTIVE SURVEILLANCE Justin Gregg, Johannes Fahrmann, Ranran Wu, Eunice Murage, Jennifer Dennison, Brian Chapin, John Davis, Peng Wei, Samir Hanash, and Carrie Daniel Justin GreggJustin Gregg More articles by this author , Johannes FahrmannJohannes Fahrmann More articles by this author , Ranran WuRanran Wu More articles by this author , Eunice MurageEunice Murage More articles by this author , Jennifer DennisonJennifer Dennison More articles by this author , Brian ChapinBrian Chapin More articles by this author , John DavisJohn Davis More articles by this author , Peng WeiPeng Wei More articles by this author , Samir HanashSamir Hanash More articles by this author , and Carrie DanielCarrie Daniel More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002036.14AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Higher coffee intake has been associated with lower incidence of both localized and aggressive prostate cancers. Similarly, we have shown that coffee may also lower risk of grade group (GG) progression in men with localized prostate cancer enrolled on active surveillance. Further, caffeine metabolism genotype may modify this relationship by decreasing the risk of progression among men who are fast metabolizers. We set out to determine if coffee- and caffeine-related metabolites, as measured in the plasma of men enrolled on active surveillance, were associated with time to GG progression. METHODS: Prostate cancer patients with localized GG 1 or 2 disease enrolled on a prospective active surveillance trial for at least 6 months with baseline plasma samples were included in this study (n=703). The surveillance protocol included a standardized follow-up regimen consisting of biennial PSA and exam and yearly biopsy, except in the cases of prior negative biopsy. Disease progression was defined as an increase in GG following confirmatory biopsy. Metabolomic analyses of baseline plasma were performed on Xevo GS-X2 quadrupole time-of-flight mass spectrometers using a 2D column configuration. Data processing and peak annotations were performed using an in-house automated pipeline. Cox proportional hazards models were used to evaluate associations of detectable baseline caffeine and coffee metabolites with progression free survival after accounting for patient, pathologic, and lifestyle factors. RESULTS: The mean age of men in the cohort was 63.5 years (STD 8.0) and the average baseline PSA was 4.7 ng/ml (STD 3.2). Over a median follow-up of 36 months (range 6-126), 131/703 (18.6%) of men had documented GG progression. Of the three baseline metabolites detected in all patients, higher caffeine level (HR 1.19, 95% CI 1.003-1.40, p=0.05), but not trigenolline (HR 1.06, 95% CI 0.96-1.18, p=0.23) or paraxanthine (0.93 95% CI 0.72-1.21, p=0.61), was associated with shortened progression free survival. CONCLUSIONS: Although prior data from us and others suggest that intake of coffee may be beneficial for men with prostate cancer, circulating baseline caffeine levels may be associated with GG progression in men on active surveillance. Taken together, these data suggest a potential complex relationship between coffee, caffeine and localized prostate cancer aggressiveness, though further studies that include genetic factors, additional metabolites and dose-response analyses are urgently needed. Source of Funding: Gregg: UT MD Anderson Prostate Cancer SPORE Career Enhancement Award; P50 CA140388 Logothetis (PI) © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e571-e571 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Justin Gregg More articles by this author Johannes Fahrmann More articles by this author Ranran Wu More articles by this author Eunice Murage More articles by this author Jennifer Dennison More articles by this author Brian Chapin More articles by this author John Davis More articles by this author Peng Wei More articles by this author Samir Hanash More articles by this author Carrie Daniel More articles by this author Expand All Advertisement Loading ...